Adherence to urate-lowering therapy

Southern Medical Journal

Volumn 102, Issue 1, 2009, Pages 114-115

  Day, Richard O ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIUROLITHIASIS AGENT; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; URIC ACID; ANTIGOUT AGENT;

AFRICAN AMERICAN; DRUG TREATMENT FAILURE; GOUT; HUMAN; LETTER; LOW DRUG DOSE; PATIENT COMPLIANCE; URIC ACID BLOOD LEVEL; UROLITHIASIS; BLOOD; FEMALE; MALE;

FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MEDICATION ADHERENCE; URIC ACID;

EID: 59249107830     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31819042a0     Document Type: Letter

References (3)

1. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-1581.
2. Solomon D, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;57:609-613.
3. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.